1. Home
  2. MEIP vs WVVI Comparison

MEIP vs WVVI Comparison

Compare MEIP & WVVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MEIP
  • WVVI
  • Stock Information
  • Founded
  • MEIP 2000
  • WVVI 1983
  • Country
  • MEIP United States
  • WVVI United States
  • Employees
  • MEIP N/A
  • WVVI N/A
  • Industry
  • MEIP Biotechnology: Pharmaceutical Preparations
  • WVVI Beverages (Production/Distribution)
  • Sector
  • MEIP Health Care
  • WVVI Consumer Staples
  • Exchange
  • MEIP Nasdaq
  • WVVI Nasdaq
  • Market Cap
  • MEIP 19.5M
  • WVVI 16.5M
  • IPO Year
  • MEIP 2003
  • WVVI N/A
  • Fundamental
  • Price
  • MEIP $2.78
  • WVVI $3.31
  • Analyst Decision
  • MEIP Hold
  • WVVI
  • Analyst Count
  • MEIP 2
  • WVVI 0
  • Target Price
  • MEIP $7.00
  • WVVI N/A
  • AVG Volume (30 Days)
  • MEIP 53.1K
  • WVVI 7.6K
  • Earning Date
  • MEIP 11-12-2024
  • WVVI 11-12-2024
  • Dividend Yield
  • MEIP N/A
  • WVVI N/A
  • EPS Growth
  • MEIP N/A
  • WVVI N/A
  • EPS
  • MEIP N/A
  • WVVI N/A
  • Revenue
  • MEIP N/A
  • WVVI $39,259,016.00
  • Revenue This Year
  • MEIP N/A
  • WVVI N/A
  • Revenue Next Year
  • MEIP $300.00
  • WVVI N/A
  • P/E Ratio
  • MEIP N/A
  • WVVI N/A
  • Revenue Growth
  • MEIP 33.76
  • WVVI N/A
  • 52 Week Low
  • MEIP $2.61
  • WVVI $3.26
  • 52 Week High
  • MEIP $6.91
  • WVVI $5.44
  • Technical
  • Relative Strength Index (RSI)
  • MEIP 36.75
  • WVVI 42.74
  • Support Level
  • MEIP $2.76
  • WVVI $3.32
  • Resistance Level
  • MEIP $2.91
  • WVVI $3.40
  • Average True Range (ATR)
  • MEIP 0.11
  • WVVI 0.10
  • MACD
  • MEIP -0.04
  • WVVI -0.00
  • Stochastic Oscillator
  • MEIP 5.13
  • WVVI 14.29

About MEIP MEI Pharma Inc.

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

About WVVI Willamette Valley Vineyards Inc.

Willamette Valley Vineyards Inc produces and sells premium, super-premium, and ultra-premium wines. The grapes are harvested, fermented, and made into wine at the company's Turner winery, and the wines are sold principally under its Willamette Valley Vineyards label and also under the Griffin Creek, Tualatin Estate, Pambrun, Maison Bleue, Natoma, Metis, and Elton labels. It operates under two operating segments, direct sales and distributor sales. Direct sales include retail sales in its tasting room and remote sites, wine club sales, online sales, on-site events, kitchen and catering sales, and other sales made directly to the consumer without the use of an intermediary. Distributor sales include all sales through a third party where prices are given at a wholesale rate.

Share on Social Networks: